安杰思(688581.SH)：2025年度净利润2.23亿元，同比下降24.06%

Core Viewpoint - Anjias (688581.SH) reported a decline in revenue and net profit for the fiscal year 2025, primarily due to industry challenges such as domestic medical insurance procurement policies and increased competition in the minimally invasive endoscopic treatment sector [1][2]. Group 1: Financial Performance - The company achieved total operating revenue of 597 million yuan, a decrease of 6.19% compared to the same period last year [1]. - The net profit attributable to the parent company was 223 million yuan, down 24.06% year-on-year [1]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 191 million yuan, reflecting a decline of 29.81% compared to the previous year [1]. Group 2: Industry Challenges - The medical device industry faced significant challenges due to domestic medical insurance centralized procurement and overseas tariff policies, impacting the company's performance [1]. - Increased competition in the minimally invasive endoscopic treatment field has also contributed to the pressure on the company's financial results [1]. Group 3: Strategic Initiatives - The company remains focused on research and innovation in minimally invasive endoscopic treatment devices and high-end diagnostic equipment, aiming to enhance product coverage [2]. - Investments in automation production lines have been increased to maintain stable gross margins and improve market competitiveness [2]. - The company is executing a globalization strategy, enhancing local operations in the Netherlands and developing a production base in Thailand, while also deepening channel management and exploring emerging markets [2]. - Significant investments have been made in multiple research and development pipelines, supporting a dual-driven development strategy for diagnostic equipment and medical devices, laying a solid foundation for business growth in 2026 [2].